This study compares the immune properties of peripheral blood stem cell (PSC) products mobilized with different hematopoietic growth factors (HGFs) as well as apheresis products and peripheral blood leukocytes (PBL) from normal individuals. We found that monocytes in mobilized PSC products appear to inhibit T cell function independent of whether granulocyte colonystimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) was used for mobilization. In addition, the GF used to mobilize the stem cell product may be less important to the CD4:CD8 ratio than the extent of prior chemotherapy, as we found an inverse correlation between chemotherapy and the CD4:CD8 ratio. In other observations, all apheresis products, whether mobilized or unmobilized, contained significantly more monocytes compared to normal PBL. The mononuclear cells (MNC) from G-CSF or GM-CSF mobilized PSC products had a similar T cell phytohemagglutinin (PHA) mitogenic response that was significantly lower (P = 0.001 and P = 0.005, respectively) than non-mobilized apheresis products. We also examined the T cell inhibitor (TI) activity of the MNC from the PSC products for allogeneic lymphocyte proliferation and found that PSC products significantly reduced the proliferation of allogeneic PBL to PHA. A significant correlation (P = 0.001, r = 0.517) between the frequency of monocytes and TI activity also was observed.
following transplant compared to normal individuals. PSCT patients, however, have a more rapid immune recovery than do BMT patients. [5] [6] [7] 10 Stem cells are mobilized from the bone marrow (BM) into the peripheral blood (PB) after myelosuppressive chemotherapy, 12 chemotherapy combined with HGFs [13] [14] [15] [16] [17] or during administration of HGFs. [18] [19] [20] [21] [22] [23] [24] Accelerated hematopoietic recovery is observed following PSCT as compared to transplantation with steady-state BM and is only observed when peripheral blood stem cell (PSC) products are collected after mobilization. 21, 24, 25 The choice of HGF used for mobilization may also be important as granulocyte-macrophage colony-stimulating factor (GM-CSF) interacts with earlier progenitors than does granulocyte colony-stimulating factor (G-CSF) 26 and increases the frequency of granulocytes, macrophages, eosinophils, megakaryocytes, erythroid precursors, and dendritic cells from hematopoietic progenitors. 27 In addition, the administration of GM-CSF 28 or G-CSF 29 after autologous BMT or PSCT also can enhance the endogenous cytotoxic and antimicrobial 30 activity of immune cells. G-CSF is used most frequently for mobilization and has been shown to enhance the production and maturation of neutrophils in vitro and in vivo. 27, 31, 32 G-CSF is unique among the regulators of granulopoiesis in that it not only stimulates the proliferation, but also induces the terminal maturation of myeloid progenitor cells. 33 Like other cytokines, G-CSF exerts a pleiotropic effect on different cell populations. The G-CSF receptor can be found on myeloid progenitor cells, mature neutrophils, platelets, monocytes, and some T and B lymphoid cell lines. 33 In addition, the PSC pool can be expanded by both G-CSF and GM-CSF. [34] [35] [36] While it is well documented that the injection of HGFs mobilizes stem cells with different hematopoietic properties dependent on the HGF, no studies to date have compared the immunologic characteristics of PSC products mobilized with different HGFs.
Analysis of G-CSF mobilized PSC products has shown that they contain at least three times more T cells than steady-state BM products. However, the frequency of natural killer (NK) and T cells in these PSC products is in the range expected for normal PB. 37 We and others have reported 9, 38 that GM-CSF mobilized PSC products have a high frequency of monocytes. Furthermore, the phenotypic analysis of mobilized PSC products revealed normal levels of CD4
+ cells and an increased frequency of CD8 + cells, which results in a decreased CD4:CD8 cell ratio as compared to the PB of normal individuals.
While the effects of GM-CSF and G-CSF on myeloid cells have been studied, the effect of HGF mobilization on lymphoid cells is not well understood. GM-CSF has been reported to amplify interleukin (IL)-2 supporting T cell proliferation, 39 and in patients with non-Hodgkin's lymphoma (NHL), there is an increase in the absolute lymphocyte count, particularly activated lymphocytes after GM-CSF administration. 40 Other reports 41 have examined the ability of GM-CSF to induce T cell proliferation and found that it upregulated the expression of IL-2 receptors on T lymphocytes. We report here a comparison of the effect of G-CSF and GM-CSF mobilization on lymphocyte and monocyte function and phenotype in PSC products.
Materials and methods

Patients and control group
A total of 54 apheresis products, including HGF mobilized leukapheresis products from 36 patients and 18 non-mobilized apheresis products from healthy donors, were examined. The samples were divided into three groups, according to whether HGF was used for mobilization and whether G-CSF or GM-CSF was used for mobilization. PSC apheresis products were collected from 21 patients following GM-CSF and from 15 patients following G-CSF mobilization. NHL patients who were eligible for PSCT at the University of Nebraska Medical Center (UNMC) were entered into these studies. The samples were obtained using protocols approved by the Institutional Review Board of UNMC and following written informed consent. The clinical characteristics of both groups are shown in Table 1 . Using the same protocol as for the cancer patients, non-mobilized, apheresis products were obtained from normal donors and served as a control group for the mobilized PSC apheresis. 
Proliferation assay
Phytohemagglutinin (PHA)-induced T cell proliferation was measured by determining 3 H-thymidine incorporation into DNA. Cells (100 l/well) were plated in quadruplicate in flat-bottomed wells of microtiter plates at 1 × 10 6 cells/ml. The cells were cultured in PHA (100 l/well) at a final concentration of 0.5 g/ml of media. On day 3, the wells were pulsed for 18 h with 1 Ci of 3 H-thymidine (Amersham Life Sciences; Arlington Heights, IL, USA) and the cells harvested on day 4 using an automatic multiwell harvester (Packard Instruments, Downers Grove, IL, USA). The filters were allowed to air dry, scintillation cocktail was added, and the samples were counted in a Packard multi-well beta-plate counter. In all studies, a control of normal peripheral blood leukocytes (PBL) was included and the data are reported as the percent of the control sample.
Flow cytometry
Flow cytometric analyses were used for the phenotyping studies. The cell populations were studied prior to FicollHypaque separation and erythrocytes removed by lysis. Aliquots of 5 × 10 4 cells were stained with biotin-conjugated monoclonal antibodies (MoAb) to CD8 and CD14, a fluorescein isothiocyanate (FITC)-labeled MoAb to CD3, and a phycoerythrin (PE)-labeled MoAb to CD4. After incubation and washing, streptavidin allophycocyanin (APC) was added as the third fluorochrome. The data were acquired on a FACStar Plus using a 40 mw, 488 nm argon laser and a 100 mW, 647 nm HeNe laser for excitation. Detailed data analysis was performed using Paint-A-Gate Plus software from Becton Dickinson (San Jose, CA, USA).
T cell inhibition assay
The coculture assay used to measure the cellular inhibition of T cell function has been described previously. 9, 38, 42, 43 Briefly, Ficoll-Hypaque purified, normal PBL (1 × 10 5 ) as responder cells were cocultured with varying numbers of irradiated (500 cGy) putative inhibitor cells (MNC from PB or PSC product) starting at an inhibitor to responder ratio (I:R) of 4:1. Four, two-fold dilutions of inhibitor cells (50 l) were made in 96-well flat bottom plates. The responder cells were then added (50 l) together with the PHA (100 l) to achieve 0.5 g/ml.
Cells were cultured at 37°C (5% CO 2 ) for 3 days in RPMI-1640 medium plus 10% FBS and the mitogenic response by the responder population assayed by pulsing with 1 Ci/well 3 H-thymidine over the final 18 h of culture. Cells were harvested with a multi-well harvester onto a fiberglass strip and the radioactivity determined in a Packard beta scintillation counter as described above. The data are presented as the mean Ϯ the standard error of the mean (s.e.m.). Results were calculated as:
This was then normalized to the activity of normal PB analyzed in parallel experiments and reported as a percent of control cells.
Statistical analysis
SPSS for Windows was used to apply Pearson, Kendall's tau-b, and Spearman correlation analyses (two-tail) to the data. The independent sample's t-test was used to compare the difference between two independent means. Mean differences were considered significant when P р 0.05.
Results
Monocyte and T cell frequency within PSC products
The frequency of monocytes (mean Ϯ s.e.m.) in mobilized PSC products, 30.3 Ϯ 3.2% and 41.3 Ϯ 4.6% for GM-CSF and G-CSF mobilized products, respectively, were significantly higher (P р 0.0001 for both) than for non-mobilized apheresis products (11.7 Ϯ 1.1%) (Figure 1 ). In addition to the significant increase in the frequency of monocytes in the mobilized PSC products, there was also a significant increase in the frequency of monocytes in the non-mobilized apheresis products from normal individuals as com- pared to normal PB (4.1 Ϯ 0.7%), suggesting that apheresis enriches for monocytes. Although the frequency of monocytes from G-CSF mobilized PSC products was slightly higher than that found in PSC products mobilized with GM-CSF, it did not achieve significance (P = 0.061). Thus, it appears that the frequency of monocytes within mobilized PSC products was independent of the type of HGF used in mobilization. The frequency of T cells within mobilized and non-mobilized products was similar to that found in normal PB. Thus, there were 16.2 Ϯ 2.2% CD3
+ cells in G-CSF mobilized PSC products as compared to 14.8 Ϯ 7.9% CD3 + cells in GM-CSF mobilized products (P = 0.629). The frequency of CD3
+ cells in normal PB, which has not been Ficolled, (17.2 Ϯ 2.3%) also was statistically identical to that observed in the G-CSF products (P = 0.771) and GM-CSF mobilized PSC products (P = 0.421). In contrast to the similar frequencies of CD3 + cells found in mobilized PSC products and normal PB, the frequencies of CD4
+ and CD8
+ cells differ significantly between the two mobilized PSC products (P = 0.016 and 0.043, respectively), ie a significant increase in CD4 + cells and a significant decrease in CD8 + cells were found in G-CSF mobilized products relative to GM-CSF mobilized products. The frequencies of CD4 + cells (lymphocyte gate) within G-CSF and GM-CSF mobilized PSC products and normal PB were 35.2 Ϯ 2.14%, 22.17 Ϯ 5.06% and 31.1 Ϯ 3.75%, respectively, while CD8 + cells were 24.7 Ϯ 3.68%, 35.5 Ϯ 5.25% and 18.6 Ϯ 2.84%, respectively. This resulted in a significant difference (P = 0.034) in the CD4:CD8 cell ratio between GM-CSF (0.898 Ϯ 0.028) and G-CSF mobilized PSC products (1.99 Ϯ 0.47). The CD4:CD8 ratio of the GM-CSF mobilized products, but not the G-CSF mobilized products, also differed significantly (P = 0.014) from normal PB cells (1.87 Ϯ 0.2).
T cell function
T cell proliferation by the MNC from PSC products was always compared to the PHA response of MNC from normal PBL examined at the same time. The proliferation of lymphocytes from PSC products (c.p.m. experimental) is reported as the percent proliferation of lymphocytes from normal PB (c.p.m. control) to normalize for day-to-day variability. Although the response to PHA mitogenesis by G-CSF was lower than that of GM-CSF mobilized apheresis products (16.8 Ϯ 5.4% vs 32.3 Ϯ 12% of control, respectively), it was not a significant difference (P = 0.257) (Figure 2 ). This suggests that the low PHA mitogenic response was independent of G-CSF or GM-CSF mobilization and did not correlate with the extent of prior chemotherapy (analysis not shown). Further, MNC from PSC products mobilized with G-CSF or GM-CSF had a decreased PHA mitogenic response, which was significantly lower (P = 0.0001 and P = 0.005, respectively) than that of nonmobilized apheresis products (94.6 Ϯ 16.3%). Thus, HGF mobilization contributes to the decreased PHA proliferation by MNC from apheresis products and is independent of the HGF used (G-CSF vs GM-CSF). Percent of control (PBL-%) Figure 2 Response to PHA by irradiated MNC from PSC products that were non-mobilized or mobilized with G-CSF or GM-CSF. The results are normalized compared to that of MNC from normal donors compared the same day. Cells from apheresis products were cultured at 1 ϫ 10 6 /ml in PHA at a final concentration of 0.5 g/ml for 72 h followed by 3 
Cellular T cell inhibitor (TI) activity
We previously reported that monocytes from mobilized PSC products have the ability to kill activated T cells by apoptosis. 43 To determine whether the HGF used for the mobilization of stem cells affected TI activity, irradiated MNC from G-CSF and GM-CSF mobilized PSC products were added in graded numbers to cultures of allogeneic MNC with PHA. Figure 3 shows the ability of MNC from PSC products to inhibit the mitogenic response to PHA. The data are reported as the percent inhibition of T cell blastogenesis at I:R ratios of 4:1, 2:1 and 1:1 as compared to irradiated MNC from normal PB. The proliferative response of the allogeneic T cells to PHA at each I:R ratio in the presence of irradiated MNC from G-CSF or GM-CSF mobilized PSC products was similar (4:1, 38.3 Ϯ 12.3% vs 51.3 Ϯ 15.5%; 2:1, 30.6 Ϯ 8.8% vs 40 Ϯ 9.8%; and 1:1, 18.6 Ϯ 9.6% vs 21.3 Ϯ 7.6%, respectively). Thus, the cells from both HGF mobilized PSC products were potent inhibitors of normal MNC proliferation in response to PHA, while cells from non-mobilized apheresis products showed a slight or negative inhibition (Ϫ14.5 Ϯ 12%, Ϫ5.5 Ϯ 7% and Ϫ7.7 Ϯ 6%, at I:R ratios of 4:1, 2:1 and 1:1, respectively).
Clinical and immunologic correlations
As shown in Table 1 , patients mobilized with GM-CSF received significantly (P = 0.0001) more chemotherapy compared to patients mobilized with G-CSF (8.6 Ϯ 1.1 vs 1.8 Ϯ 0.3 months, respectively). There was no correlation between the number of months of chemotherapy prior to transplant and PHA or TI functional activity. Interestingly, an analysis of the CD4:CD8 cell ratio with the extent of prior chemotherapy (months) revealed an inverse correlation (Kendall's tau-b P = 0.021, r = Ϫ0.337 and Spear- man's rho P = 0.013, r = −0.479 analyses), suggesting an association between these two parameters. As shown in Figure 4 , the frequencies of monocytes in the mobilized or non-mobilized products significantly correlated (r = 0.517 and P = 0.001) with TI activity. In addition, the inhibition of T cell blastogenesis, and level of TI activity, was associated with HGF mobilization and independent of the HGF used for mobilization. In other studies, we have found that monocytes at a high frequency result in TI activity, 43 and their removal restores T cell function.
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Discussion
Stem cell mobilization is used to obtain PSC products that accelerate hematopoietic recovery following HDT and appear to contain a low frequency of contaminating tumor cells. However, the influence of the mobilization procedure and the HGF used on lymphocyte function within the mobilized PSC products has not been studied extensively. Despite the loss of T cell function in stem cell products, a similar frequency of lymphocytes is found in PSC products mobilized with HGF alone (G-CSF or GM-CSF) as compared to normal PB. 46 However, little data exist comparing the effect of G-CSF to GM-CSF [47] [48] [49] [50] on the immune phenotype and function of the PSC products. Because we have found that monocytes in GM-CSF mobilized PSC products can inhibit T cell proliferation via the induction of apoptosis, 43, 44 the purpose of this study was to compare the immune-mediating effect of mobilization with G-CSF vs GM-CSF.
Monocytes from GM-CSF mobilized PSC products were reported by Triozzi et al 51 to have antitumor and accessory immune activities. In contrast, we previously have reported 44, 52 that phagocytic CD14 + cells from GM-CSF mobilized PSC products can inhibit T and NK cell functions. [43] [44] [45] These monocytes express a high level of HLA-DR and low or non-existent levels of B7-1 (CD80). In addition, these 'activated monocytes' have increased levels of IL-10 mRNA, 53 which might relate to the low expression of CD80 on the mobilized monocytes. [54] [55] [56] Furthermore, the GM-CSF mobilized monocytes induced the apoptosis of activated lymphocytes. 43 Recently, Mielcarek et al 57 also reported TI activity within G-CSF mobilized PSC products used in allotransplantation, which may result in lower graftversus-host disease (GVHD). In other studies, when monocytes were removed from PSC products, T cell function returned to normal values [43] [44] [45] and TI activity was lost. 43 We report here that HGF mobilized apheresis products also have a significant increase in monocyte frequency compared to normal PB and non-mobilized apheresis products. Non-mobilized apheresis products also have a significantly higher monocyte frequency than normal PB, which suggests that apheresis enriches monocytes as well as CD34
+ cells. In addition, the non-mobilized apheresis products have a significantly higher PHA response than PSC products mobilized with either G-CSF or GM-CSF. Further, the MNC from mobilized PSC products have significantly higher TI activity for allogeneic lymphocyte proliferation compared to MNC from non-mobilized products. The monocyte content of the leukapheresis products directly correlated with TI activity. However, the TI activity was independent of the type of HGF used in mobilization. Further, the depressed PHA mitogenic response was not due to a decreased CD3 + cell frequency, as the frequency of CD3 + cells within normal PB and G-CSF and GM-CSF mobilized PSC products was statistically similar. Thus, the depressed T cell function is not due to a loss of T cells in the PSC product. This is consistent with prior studies 7 where the monocytes were shown to actively inhibit T cell proliferation. 43, 44, 46 In contrast to the similar frequency of CD3 + cells, there was a significant decrease in the frequency of CD4 + cells in GM-CSF mobilized products and a significant increase in the frequency of CD8 + cells related to G-CSF products. This resulted in a significant difference in the CD4:CD8 ratio. Whilst not directly comparable, this differs from the results of San-Miguel et al 58 who found that GM-CSF administration resulted in a higher frequency of CD4
+ cells in stem cell products. However, because our studies examined patients at different disease stages, there were significant differences between the two cohorts in the extent of prior chemotherapy. In agreement with our prior studies, 6 which demonstrated a correlation between PHA response and prior chemotherapy, we found an inverse relationship between chemotherapy and the CD4:CD8 ratio. Thus, in these studies the extent of prior chemotherapy is a critical determinant in the CD4:CD8 ratio rather than the HGF used in mobilization. This does not preclude a differential effect by HGFs on lymphocyte populations and function, but does demonstrate that additional factors can compound the interpretation of these data. Indeed, preclinical studies with G-CSF have revealed a shift toward type 2 cytokine production. 59 Recently, it was reported that an increase in monocytes predicts an optimal mobilization of CD34 + cells after chemotherapy followed by G-CSF administration 24 and was a useful parameter to follow in the timing of PSC collections. Further, it has been shown that the efficacy of CD34 + stem cell purification from mobilized PSC is inversely proportional to the number of monocytes in the initial cell population. Nakamura et al 60 also reported an increased purification of CD34 + cells from mobilized PSC products followed depletion of adherent cells. Similarly, Yamaguchi et al 61 reported an inverse correlation between the frequency of CD14 + cells in the initial cell population and the efficacy of CD34 + cell purification using immunomagnetic microspheres. Overall, we suggest that the depletion of HGF mobilized monocytes from within PSC products might provide a strategy with therapeutic implications for hematologic and immunologic reconstitution post-transplantation. We also speculate that the HGF mobilized monocytes are at least partially responsible for the immune dysfunction found post-transplantation, a hypothesis currently under investigation.
Schneider et al 48 have suggested that both the mobilization regimen and pre-treatment patient characteristics are critical to the successful mobilization of PSC autografts. In these studies, the mobilization of PSC with G-CSF or GM-CSF in patients who had received prior myelosuppressive therapy produced autografts that were deficient in committed progenitors and absolutely deficient in primitive progenitors. In our studies, there was a significant difference in the extent of prior chemotherapy between the two groups of mobilized patients. Nonetheless, the T cell proliferative response to PHA from the G-CSF mobilized PSC products was insignificantly (P = 0.257) lower than that of GM-CSF mobilized apheresis products (16.8 Ϯ 5.4% of control vs 32.3 Ϯ 12% of control, respectively). Further, we found that the negative effect of monocytes on T cell proliferation was independent of whether G-CSF or GM-CSF was used for mobilization and the frequency of CD3 + cells in the products. Thus, the low PHA proliferative response of MNC from mobilized PSC products is due to the presence of a high frequency of monocytes, while prior treatment with chemotherapy affects the CD4:CD8 cell ratio. In keeping with this conclusion, data reported by Mielcarek et al 46 found similar TI activity in leukapheresis products from normal donors after G-CSF mobilization. In conclusion, we suggest that the extent of prior chemotherapy and the mobilizing HGF are independent of TI activity for allogeneic lymphocyte proliferation. Furthermore, an inverse correlation is found between the frequency of monocytes in apheresis products and TI activity in agreement with our previous reports of monocytes as mediators of TI activity. [43] [44] [45] 
